Pembrolizumab news (page 2)

All news on Pembrolizumab (also known as KEYTRUDA and KEYTRUDA®): plants, production capacities, investments and involved companies.

19 October 2025

Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer

Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.
18 October 2025

Merck and Eisai: KEYTRUDA and LENVIMA Show 5-Year Survival Benefit in Advanced Endometrial Carcinoma

KEYTRUDA and LENVIMA improve 5-year survival rates in advanced endometrial carcinoma compared to chemotherapy, with consistent results across patient subgroups.
18 October 2025

Merck's KEYTRUDA Plus Chemotherapy Reduces Disease Progression Risk in Platinum-Resistant Ovarian Cancer

KEYTRUDA with chemotherapy shows significant survival benefits in platinum-resistant ovarian cancer, leading to FDA priority review for expanded use.
18 October 2025

Merck: KEYTRUDA and Padcev Cut Bladder Cancer Risks Pre- and Post-Surgery

KEYTRUDA and Padcev improve survival rates in muscle-invasive bladder cancer patients ineligible for cisplatin, showing significant event-free and overall survival benefits.
16 October 2025

Merck's KEYNOTE-B96 Trial Shows Improved Survival in Platinum-Resistant Ovarian Cancer

The trial showed improved overall survival with KEYTRUDA in platinum-resistant ovarian cancer, with consistent safety and no new signals. Results to be presented at a future medical meeting.
9 October 2025

Merck Showcases Oncology Advances at ESMO 2025

Merck presents positive data on KEYTRUDA and other investigational medicines for various cancers, highlighting progress in treatment and research at ESMO 2025.

Who will be producing Pembrolizumab in the future?

Find out with chemXplore Alpha

Learn more

19 September 2025

FDA Approves Merck's Subcutaneous KEYTRUDA QLEX for Solid Tumors

KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.

← Previous